Quick Answer
PALISADE BIO, INC. reported Operating Income Loss of -$18.06 million for the year ending 2025.
- PALISADE BIO, INC. showed a decrease of -21.5% in Operating Income Loss from 2024 to 2025.
- This data is from PALISADE BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), PALISADE BIO, INC.'s Operating Income Loss has declined by 72.5%.
- Historical annual values: Fiscal year 2025: -$18.06 million | Fiscal year 2024: -$14.86 million | Fiscal year 2023: -$13.07 million | Fiscal year 2022: -$15.72 million | Fiscal year 2021: -$41.85 million | Fiscal year 2020: -$9.30 million | Fiscal year 2019: -$8.63 million | Fiscal year 2018: -$8.26 million | Fiscal year 2017: -$13.31 million | Fiscal year 2016: -$20.64 million | Fiscal year 2015: -$19.16 million | Fiscal year 2014: -$17.44 million | Fiscal year 2013: -$12.52 million | Fiscal year 2012: -$10.16 million | Fiscal year 2011: -$12.99 million | Fiscal year 2010: -$15.18 million | Fiscal year 2009: -$10.47 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: